Abstract
The willingness to pursue treatment for erectile dysfunction (ED) is dependent on many factors but associated patient bother and distress is a key factor. Other relevant factors to consider include the presence of contraindications to therapy, the absence of partner, lack of willingness of partner to participate in sexual relations, and cost of treatment. As outlined in the other ED algorithms, some patients will have undergone extended evaluation and others will have forgone further assessment. While 50 % of men over 40 years of age have some degree of ED, less than 10 % ever seek treatment, presumably because many of them are not bothered by the ED and are capable of having satisfactory sexual relations despite their ED.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Suggested Reading
Corona G, Mondaini N, Ungar A, Razzoli E, Rossi A, Fusco F. Phosphodiesterase type 5 (PDE5) inhibitors in erectile dysfunction: the proper drug for the proper patient. J Sex Med. 2011;8(12):3418–32.
Garcia JA, Sanchez PE, Fraile C, Escovar P. Testosterone undecanoate improves erectile dysfunction in hypogonadal men with the metabolic syndrome refractory to treatment with phosphodiesterase type 5 inhibitors alone. Andrologia. 2011;43(5):293–6.
Leungwattanakij S, Flynn Jr V, Hellstrom WJ. Intracavernosal injection and intraurethral therapy for erectile dysfunction. Urol Clin North Am. 2001;28(2):343–54.
Melnik T, Soares BG, Nasello AG. The effectiveness of psychological interventions for the treatment of erectile dysfunction: systematic review and meta-analysis, including comparisons to sildenafil treatment, intracavernosal injection, and vacuum devices. J Sex Med. 2008;5(11):2562–74.
Montague DK, Barada JH, Belker AM, et al. Clinical guidelines panel on erectile dysfunction: summary report on the treatment of organic erectile dysfunction. The American Urological Association. J Urol. 1996;156(6):2007–11.
Montorsi F, Adaikan G, Becher E, Giuliano F, Khoury S, Lue TF, et al. Summary of the recommendations on sexual dysfunctions in men. J Sex Med. 2010;7(11):3572–88.
Mulhall JP, Montorsi F. Evaluating preference trials of oral phosphodiesterase 5 inhibitors for erectile dysfunction. Eur Urol. 2006;49(1):30–7.
Mulhall JP, Althof SE, Brock GB, Goldstein I, Junemann KP, Kirby M. Erectile dysfunction: monitoring response to treatment in clinical practice–recommendations of an international study panel. J Sex Med. 2007;4(2):448–64.
Qaseem A, Snow V, Denberg TD, et al. Hormonal testing and pharmacologic treatment of erectile dysfunction: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2009;151(9):639–49.
Tsertsvadze A, Fink HA, Yazdi F, et al. Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis. Ann Intern Med. 2009;151(9):650–61.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this chapter
Cite this chapter
Mulhall, J.P., Stahl, P.J., Stember, D.S. (2014). Erectile Dysfunction: Treatment. In: Clinical Care Pathways in Andrology. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-6693-2_9
Download citation
DOI: https://doi.org/10.1007/978-1-4614-6693-2_9
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-6692-5
Online ISBN: 978-1-4614-6693-2
eBook Packages: MedicineMedicine (R0)